Yu-Wen Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yu-Wen Cheng has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Gavin Y. Oudit
Department of Medicine, University of Alberta, Edmonton, Canada
2 shared publications - Jiuchang Zhong
Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
2 shared publications - Bei Song
Zhejiang CHR Intelligent Equipment Co., Ltd.,Technology Department,Zhejiang,P.R. China
1 shared publication - Haiyan Jin
Bioinformatics and Molecular Design Research Center (BMDRC), Songdogwahak-ro 85, Yeonsu-gu, Incheon 21983, Republic of Korea
1 shared publication - Haiyan Liu
Department of Statistics, University of Leeds, Leeds LS2 9JT, UK
1 shared publication - Jing Li
Department of Radiology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Evaluating the Efficacy and Safety of Kinesiology Tape Wrapping as Adjunct Therapy for Epidermal Growth Factor Receptor–Induced Paronychia
Background: Current therapies for epidermal growth factor receptor inhibitor (EGFRI)–related paronychia demonstrate effectiveness; however, some patients respond poorly and experience recurrent painful granulation tissue, particularly in weight‐bearing areas such as the big toes. Based on promising results from our previous pilot study by Hsu and colleagues, novel kinesiology tape wrapping, which physically shields the inflamed periungual tissue from irritation by the nail plate, has emerged as a potentially effective adjunct therapy. Objectives: This open‐label, randomized‐controlled, single‐center study was aimed to evaluate the efficacy and safety of kinesiology tape wrapping in cancer patients with EGFRI‐related paronychia. Materials and Methods: Eligible participants were assigned to receive either kinesiology tape wrapping in combination with conventional therapies or conventional therapies alone for 12 weeks. Efficacy outcomes, including the reduction of subjective pain assessed by the numerical rating scale (NRS) and the objective single‐digit scoring system for paronychia related to oncologic treatments (single‐digit SPOT), as well as adverse events (AEs), were recorded at baseline and at Weeks 1, 2, 4, 8, and 12 postenrollment. Results: A total of 24 patients were randomized, of which, 22 qualified for analysis. The rate of continuous tape use was 36.3%. At Week 12, pain NRS scores showed no significant differences between groups, while patients treated with continuous or intermittent kinesiology tape wrapping demonstrated notably greater reductions in single‐digit SPOT scores compared to those receiving conventional therapy alone (NRS: 3.27 vs. 2.78, p = 0.586; single‐digit SPOT: 5.32 vs. 1.52, p = 0.022). No serious AEs were reported. Conclusion: Kinesiology tape wrapping is an effective and safe adjunct noninvasive therapy that offers additional benefits in managing EGFRI‐related paronychia. Further studies with longer follow‐ups and improved patient compliance may help fully evaluate its effectiveness in pain reduction. Trial Registration : ClinicalTrials.gov identifier: NCT06411093
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Open AccessEvaluating the Efficacy and Safety of Kinesiology Tape Wrapping as Adjunct Therapy for Epidermal Growth Factor Receptor–Induced Paronychia
Background: Current therapies for epidermal growth factor receptor inhibitor (EGFRI)–related paronychia demonstrate effectiveness; however, some patients respond poorly and experience recurrent painful granulation tissue, particularly in weight‐bearing areas such as the big toes. Based on promising results from our previous pilot study by Hsu and colleagues, novel kinesiology tape wrapping, which physically shields the inflamed periungual tissue from irritation by the nail plate, has emerged as a potentially effective adjunct therapy. Objectives: This open‐label, randomized‐controlled, single‐center study was aimed to evaluate the efficacy and safety of kinesiology tape wrapping in cancer patients with EGFRI‐related paronychia. Materials and Methods: Eligible participants were assigned to receive either kinesiology tape wrapping in combination with conventional therapies or conventional therapies alone for 12 weeks. Efficacy outcomes, including the reduction of subjective pain assessed by the numerical rating scale (NRS) and the objective single‐digit scoring system for paronychia related to oncologic treatments (single‐digit SPOT), as well as adverse events (AEs), were recorded at baseline and at Weeks 1, 2, 4, 8, and 12 postenrollment. Results: A total of 24 patients were randomized, of which, 22 qualified for analysis. The rate of continuous tape use was 36.3%. At Week 12, pain NRS scores showed no significant differences between groups, while patients treated with continuous or intermittent kinesiology tape wrapping demonstrated notably greater reductions in single‐digit SPOT scores compared to those receiving conventional therapy alone (NRS: 3.27 vs. 2.78, p = 0.586; single‐digit SPOT: 5.32 vs. 1.52, p = 0.022). No serious AEs were reported. Conclusion: Kinesiology tape wrapping is an effective and safe adjunct noninvasive therapy that offers additional benefits in managing EGFRI‐related paronychia. Further studies with longer follow‐ups and improved patient compliance may help fully evaluate its effectiveness in pain reduction. Trial Registration : ClinicalTrials.gov identifier: NCT06411093
- 1 October 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36, e11-E11
A1156 Cardioprotective effects of Apelin-13 on aging- and angiotensin II-mediated adverse myocardial injury and dysfunction in hypertensive mice
The apelin-APJ system and angiotensin (Ang) II-AT1 pathways have emerged as potent regulators of blood pressure and cardiovascular function. However, the interaction between the apelin and Ang system in myocardial injury remains unclear. The C57/B6 wildtype (WT), apolipoprotein E (ApoE) knockout (KO) and apelinKO mice were randomized to receive either Ang II (1.5 mg.kg-1.d-1) osmotic minipump and /or 100 ug/kg pyr1-apelin-13 for 4 weeks. 1-year aged APLN-/y mice developed increased myocardial hypertrophy and fibrosis with downregulation of ACE2 levels. Importantly, pyr1-apelin-13 reversed Ang II-mediated hypertension, myocardial apoptosis and pathological hypertrophy in both WT and ApoEKO mice. Ang II-induced cardiac fibrosis, dysfunction and altered myocardial ultrastructure were aggravated in the ApoEKO mice which were prevented by pyr1-apelin-13. Importantly, pyr1-apelin-13 attenuated Ang II-mediated pathological effects in ApoE-null hearts associated with increased levels of ACE2 and p-ERK1/2. In cultured neonatal rat cardiomyocytes and cardiofibroblasts, exposure of Ang II decreased ACE2 protein and increased superoxide generation, cellular proliferation and migration, which were rescued by pyr1-apelin-13, Akt and eNOS agonist stimulation. The increased superoxide generation and apoptosis in cultured cardiofibroblasts in response to Ang II were strikingly prevented by pyr1-apelin-13 which was partially reversed by co-treatment with the Akt inhibitor MK2206. Our data provide definitive evidence for cardioprotective roles of pyr1-apelin-13 in aging- and Ang II-mediated pathological remodeling, myocardial fibrosis and dysfunction. Targeting the apelin-APJ pathway represents a novel therapeutic approach against hypertension.
- 1 October 2018
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 36, e11-E11
A1156 Cardioprotective effects of Apelin-13 on aging- and angiotensin II-mediated adverse myocardial injury and dysfunction in hypertensive mice
The apelin-APJ system and angiotensin (Ang) II-AT1 pathways have emerged as potent regulators of blood pressure and cardiovascular function. However, the interaction between the apelin and Ang system in myocardial injury remains unclear. The C57/B6 wildtype (WT), apolipoprotein E (ApoE) knockout (KO) and apelinKO mice were randomized to receive either Ang II (1.5 mg.kg-1.d-1) osmotic minipump and /or 100 ug/kg pyr1-apelin-13 for 4 weeks. 1-year aged APLN-/y mice developed increased myocardial hypertrophy and fibrosis with downregulation of ACE2 levels. Importantly, pyr1-apelin-13 reversed Ang II-mediated hypertension, myocardial apoptosis and pathological hypertrophy in both WT and ApoEKO mice. Ang II-induced cardiac fibrosis, dysfunction and altered myocardial ultrastructure were aggravated in the ApoEKO mice which were prevented by pyr1-apelin-13. Importantly, pyr1-apelin-13 attenuated Ang II-mediated pathological effects in ApoE-null hearts associated with increased levels of ACE2 and p-ERK1/2. In cultured neonatal rat cardiomyocytes and cardiofibroblasts, exposure of Ang II decreased ACE2 protein and increased superoxide generation, cellular proliferation and migration, which were rescued by pyr1-apelin-13, Akt and eNOS agonist stimulation. The increased superoxide generation and apoptosis in cultured cardiofibroblasts in response to Ang II were strikingly prevented by pyr1-apelin-13 which was partially reversed by co-treatment with the Akt inhibitor MK2206. Our data provide definitive evidence for cardioprotective roles of pyr1-apelin-13 in aging- and Ang II-mediated pathological remodeling, myocardial fibrosis and dysfunction. Targeting the apelin-APJ pathway represents a novel therapeutic approach against hypertension.
- 1 August 2011
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 8, 3915-3918
Research on security testing of information system based on interface communication
This paper firstly analyzes the security problems which the information systems are facing such as network attacks and attacks by use of communication protocol. Then it proposes a security testing platform basing on interface communication protocols in the light of the characteristics of the communication in information systems. It describes in detail the implementation of this platform. With this method, one can designs test cases to test the security of an information system according to its communication protocol of the hardware interfaces, which can satisfy different requirements of security testing of information systems.
- 1 August 2011
- Published by Institute of Electrical and Electronics Engineers (IEEE)
- Vol. 8, 3915-3918
Research on security testing of information system based on interface communication
This paper firstly analyzes the security problems which the information systems are facing such as network attacks and attacks by use of communication protocol. Then it proposes a security testing platform basing on interface communication protocols in the light of the characteristics of the communication in information systems. It describes in detail the implementation of this platform. With this method, one can designs test cases to test the security of an information system according to its communication protocol of the hardware interfaces, which can satisfy different requirements of security testing of information systems.